注意缺陷多动障碍患者精神共病与过早死亡风险的关联
ADHD与全因死亡风险升高相关,且随精神共病数目增加而显著增强;成年期早发共病主要影响自然死亡,晚发共病主要影响自杀与意外伤害等非自然死亡。
要点
- ADHD患者全因死亡率为11.57/万人年,高于非ADHD者的2.16/万人年。
- ADHD与死亡关联在成年期(HR 4.64)强于儿童期(HR 1.41)。
- 精神共病数目越多死亡风险越高,≥4种共病者HR达25.22。
核心结论
- 精神共病在ADHD全因及病因别死亡风险中起重要作用。
- 成年期早发精神共病主要贡献自然原因死亡关联,晚发共病主要影响非自然原因死亡。
研究设计与样本
- 暴露为首次临床诊断或首次处方ADHD药物,共病来自国家患者注册。
主要发现
- 随访期间ADHD组424人死亡,非ADHD组6231人死亡,死亡率分别为11.57与2.16/万人年。
- ADHD与死亡关联成年期HR 4.64(95%CI 4.11-5.25),儿童期HR 1.41(95%CI 0.97-2.04)。
- 仅ADHD者HR 1.41(95%CI 1.01-1.97),≥4种共病者HR 25.22(95%CI 19.60-32.46)。
- 成年期调整早发共病后,自然原因死亡关联减弱至无统计学意义(HR 1.32;95%CI 0.94-1.85)。
- 调整晚发精神障碍后,自杀死亡关联无统计学意义(HR 1.13;95%CI 0.88-1.45),意外伤害死亡仍显著(HR 2.14;95%CI 1.71-2.68),其他外因死亡亦显著(HR 1.75;95%CI 1.23-2.48)。
临床怎么用
- 临床应密切监测ADHD患者的精神共病,识别死亡高风险群体以开展预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A previous register-based study reported elevated all-cause mortality in attention-deficit/hyperactivity disorder (ADHD), but cause-specific risks and the potential associations of psychiatric comorbidities remain unknown. OBJECTIVES: To investigate the all-cause and cause-specific mortality risks in ADHD and to explore the potential role of psychiatric comorbidities. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study used Swedish national registers to identify 2 675 615 individuals born in Sweden from January 1, 1983, through December 31, 2009, as the study population, among whom 86 670 individuals (3.2%) received a diagnosis of ADHD during follow-up. Follow-up was completed December 31, 2013, and data were analyzed from October 2018 through March 2019. EXPOSURES: Attention-deficit/hyperactivity disorder identified by first clinical diagnosis or first prescription of ADHD medications as recorded in Swedish registers. Clinical diagnosis of psychiatric comorbidity was available in the National Patient Register. MAIN OUTCOMES AND MEASURES: All-cause and cause-specific mortalities and hazard ratios (HRs) using Cox proportional hazards regression models. RESULTS: In the overall cohort of 2 675 615 individuals, 1 374 790 (51.4%) were male (57 919 with an ADHD diagnosis) and 1 300 825 (48.6%) were female (28 751 with an ADHD diagnosis). Mean (SD) age at study entry was 6.4 (5.6) years. During follow-up, 424 individuals with ADHD and 6231 without ADHD died, resulting in mortality rates of 11.57 and 2.16 per 10 000 person-years, respectively. The association was stronger in adulthood (HR, 4.64; 95% CI, 4.11-5.25) compared with childhood (HR, 1.41; 95% CI, 0.97-2.04) and increased substantially with the number of psychiatric comorbidities with ADHD (HR for individuals with only ADHD, 1.41 [95% CI, 1.01-1.97]; HR for those with ≥4 comorbidities, 25.22 [95% CI, 19.60-32.46]). In adulthood, when adjusting for early-onset psychiatric comorbidity, the association between ADHD and risk of death due to natural causes was attenuated substantially and was no longer statistically significant (HR, 1.32; 95% CI, 0.94-1.85). When adjusting for later-onset psychiatric disorders, the association was attenuated to statistical nonsignificance for death due to suicide (HR, 1.13; 95% CI, 0.88-1.45) but remained statistically significant for death caused by unintentional injury (HR, 2.14; 95% CI, 1.71-2.68) or other external causes (HR, 1.75; 95% CI, 1.23-2.48). CONCLUSIONS AND RELEVANCE: Psychiatric comorbidity appears to play an important role in all-cause and cause-specific mortality risks in ADHD. In adulthood, early-onset psychiatric comorbidity contributed primarily to the association with death due to natural causes, whereas later-onset psychiatric comorbidity mainly influenced death due to unnatural causes, including suicide and unintentional injury. These findings suggest that health care professionals should closely monitor specific psychiatric comorbidities in individuals with ADHD to identify high-risk groups for prevention efforts.
引用
- Sun S, Kuja-Halkola R, Faraone SV, et al. Association of Psychiatric Comorbidity With the Risk of Premature Death Among Children and Adults With Attention-Deficit/Hyperactivity Disorder. JAMA Psychiatry. 2019. PMID: 31389973. doi:10.1001/jamapsychiatry.2019.1944
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。